Lilly Asia Ventures returned for the respiratory disease drug developer's series B round, having co-led its $85m series A last year.
US-based immunotherapy developer Ansun Biopharma closed an $80m series B round yesterday that included Lilly Asia Ventures, a corporate venturing representative of pharmaceutical firm Eli Lilly.
Investment manager Oceanpine Capital led the round, which was also backed by Yuanming Capital, Korea Investment Partners, Matrix Partners China, Lyfe Capital and, according to China Money Network, Junson Capital and 3E Bioventures.
Founded in 2003 with a focus on influenza, Ansun has since branched out into the development of treatments for a range…
